JoVE Journal

Cancer Research

このコンテンツを視聴するには、JoVE 購読が必要です。

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

8.7K Views

09:38 min

August 11th, 2017

August 11th, 2017

8,673 Views

0:05

Title

0:30

Determining Initial Gefitnib Concentration Using the 3-(4,5-dimethylthiazol-2-yl)-2,5- diphenylterazolium Bromide (MTT) Assay

2:15

Continuous Stepwise Dose-escalation of Gefitnib Treatment of PC-9 Cells

3:31

Determine Initial Concentration of PHA665752 Using the MTT Assay

6:37

Results: Two-step Dose-escalation Procedure to Establish Dual Resistance to EGFT-TKI and MET-TKI

8:21

Conclusion

文字起こし

The overall goal of this experiment is to discover novel mechanisms to overcome drug resistance. This method can help answer key questions in the cancer research field such as those about graft resistance. The main advantage of this technique is t

このコンテンツにアクセスするにはサインインするか無料トライアルを開始してください

An in vitro method for establishing dual resistance to an EGFR-TKI and a MET-TKI in cancer cells is described. This method is useful for developing treatments for patients with EGFR-mutations, who exhibit disease progression despite EGFR-TKI treatment with MET-amplification. It can also be modified for inhibitors targeting other molecules.

当社はcookieを使用しています。

「続行」をクリックすることで、当社のcookieへの同意となります。